Bacil Pharma share news, announcements and annual reports
BSE: 524516Pharmaceuticals & BiotechnologySmall Cap
Bacil Pharma Ltd. · Face value ₹10 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed May 1994
Last close ₹18.81up ₹0.41 (2.23%)
Share price at the BSE close on 30 Oct 2026. Previous close ₹18.40.
30 Oct: open ₹18.50, high ₹18.99, low ₹18.40
52-week range of traded prices to 30 Oct 2026
₹10.65Low, 26 Aug 2026₹61.80High, 10 Apr 2026
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹27 Cr3,172nd largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- Earlier quarters restated in the year
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Taken from the consolidated balance sheet, the company and its subsidiaries together; the P/E is on the company's own results until four consolidated quarters are filed. Price to book: how it is worked out
- 1.07
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- −0.7%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Sep 2026. Taken from the consolidated balance sheet, the company and its subsidiaries together; the P/E is on the company's own results until four consolidated quarters are filed.
- 0.00
- Volume, BSEVolume. Shares traded on the last trading day. Volume in the glossary
- 1,126
Bacil Pharma routine notices
116 filed, newest first. Page 1 of 3.
Oct 2026
Sep 2026
26 Sep · Routine
Jul 2026
Jun 2026
25 Jun · Routine
5 Jun · Routine
May 2026
28 May · Routine
Apr 2026
Mar 2026
26 Mar · Routine
Jan 2026
Dec 2025
29 Dec · Routine
Oct 2025
14 Oct · Routine
Sep 2025
Aug 2025
Jul 2025
Jun 2025
26 Jun · Routine
May 2025
27 May · Routine
Apr 2025
11 Apr · Routine
Mar 2025
27 Mar · Routine
Jan 2025
17 Jan · Routine
Dec 2024
28 Dec · Routine
24 Dec · Routine
Oct 2024
19 Oct · Routine
Sep 2024
27 Sep · Routine
Aug 2024
16 Aug · Routine
14 Aug · Routine
Jul 2024
Jun 2024
27 Jun · Routine
May 2024
22 May · Routine
Apr 2024
11 Apr · Routine
Mar 2024
29 Mar · Routine
Feb 2024
14 Feb · Routine
Jan 2024
Dec 2023
Nov 2023
Oct 2023
Sep 2023
Aug 2023
15 Aug · Routine
Jul 2023
11 Jul · Routine
Jun 2023
May 2023
Apr 2023
Mar 2023
29 Mar · Routine